Drug Trial Radar · NCT07043400
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
351
Planned (sponsor's estimate)
Start
Aug 27, 2025
Primary completion
Oct 30, 2027
Study completion Apr 22, 2028
Sponsor
- Lead sponsor
- BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
- Sponsor type
- Industry
- First posted
- Jun 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to assess the levels of drug exposure following treatment with tislelizumab administered as a subcutaneous (SC) injection compared to intravenous infusion (IV) as first-line therapy in adults with gastric or gastroesophageal junction (GEJ) that is locally advanced and cannot be surgically removed or has spread from the stomach to other areas of the body. Approximately 351 patients will be participating in this study. The study is composed of a screening period, a treatment period, and a follow-up period.
Conditions
- Metastatic Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
Interventions
Subcutaneous TislelizumabDrug
Administered by subcutaneous injection
Intravenous TislelizumabDrug
Administered by intravenous infusion
CisplatinDrug
Administered by intravenous infusion
LeucovorinDrug
Administered by intravenous infusion
5-fluorouracil (5-FU)Drug
Administered by intravenous infusion
OxaliplatinDrug
Administered by intravenous infusion
CapecitabineDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Model-Predicted Steady State Trough Concentration (Ctrough) of TislelizumabTime frame: 85 Days
- Model-Predicted Area under the Concentration-time Curve from Time Zero to 21 Days (AUC0-21d) after the First Dose of TislelizumabTime frame: 21 Days
Locations
95 sites in 16 countries. Site status is shown where the registry gives one.
Ironwood Cancer and Research Centers Chandler Ii
Chandler, Arizona · Recruiting
Cancer and Blood Specialty Clinic
Los Alamitos, California · Recruiting
UC Health Cancer Care and Hematology Clinic Memorial Hospital Central
Colorado Springs, Colorado · Recruiting
Bioresearch Partners Holding Hialeah Hospital
Hialeah, Florida · Recruiting
Orlando Health Cancer Institute Downtown Orlando
Orlando, Florida · Recruiting
Northwestern University
Chicago, Illinois · Recruiting
Hope and Healing Cancer Services
Hinsdale, Illinois · Recruiting
University of Kansas Medical Center Research Institute
Kansas City, Kansas · Recruiting
New England Cancer Specialists
Westbrook, Maine · Recruiting
St Louis Cancer Care, Llp
Bridgeton, Missouri · Recruiting
Nebraska Hematology Oncology
Lincoln, Nebraska · Recruiting
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada · Recruiting
Hunterdon Hematology Oncology
Flemington, New Jersey · Recruiting
Summit Medical Group
Florham Park, New Jersey · Recruiting
Oregon Oncology Specialists
Salem, Oregon · Recruiting
Vanderbilt University
Nashville, Tennessee · Recruiting
The University of Texas Md Anderson Cancer Center
Houston, Texas · Recruiting
Baylor Scott and White Medical Center Temple
Temple, Texas · Recruiting
Northwest Medical Specialties
Tacoma, Washington · Recruiting
Hospital Aleman
Caba, Argentina · Recruiting
Instituto Alexander Fleming (Iaf)
Ciudad Autonoma Buenos Aires, Argentina · Recruiting
Fundacion Cori Para La Investigacion Y Prevencion Del Cancer
La Rioja, Argentina · Recruiting
Krankenhaus Der Barmherzigen Schwestern Linz
Linz, Austria · Recruiting
Medical Univeristy Vienna
Vienna, Austria · Recruiting
Hospital de Amor Barretos
Barretos, Brazil · Recruiting
CECAP
Blumenau, Brazil · Recruiting
Hospital Brasilia
Brasília, Brazil · Recruiting
Hospital Universiario Onofre Lopes
Natal, Brazil · Recruiting
Hospital Sao Lucas Da Pucrs
Porto Alegre, Brazil · Recruiting
IMIP
Recife, Brazil · Recruiting
Inca Instituto Nacional de Cancer
Rio de Janeiro, Brazil · Recruiting
Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto
São José do Rio Preto, Brazil · Recruiting
Icesp Instituto Do Cancer Do Estado de Sao Paulo Octavio Frias de Oliveira
São Paulo, Brazil · Recruiting
Instituto Dor de Pesquisa E Ensino Sao Paulo
São Paulo, Brazil · Recruiting
Hospital Santa Rita de Cassia Afecc
Vitória, Brazil · Recruiting
The Second Hospital of Anhui Medical University
Hefei, Anhui, China · Recruiting
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China · Recruiting
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China · Recruiting
Anyang Tumor Hospital
Anyang, Henan, China · Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Showing 40 of 95 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.